Allergic Airway Disease Mechanisms and Management

Allergic airway disease encompasses a spectrum of conditions in which the respiratory mucosa exhibits exaggerated immune responses to otherwise innocuous inhaled substances. At the core lies an interplay between a compromised epithelial barrier, innate immune activation and a skewed adaptive response dominated by T helper 2 cells. These cells release interleukins that drive immunoglobulin E production, mast cell degranulation and eosinophil recruitment, culminating in airway hyperresponsiveness, tissue remodelling and chronic inflammation. Neural reflexes further amplify bronchoconstriction and mucus secretion, linking upper and lower airway sites in a unified inflammatory circuit. Management strategies range from allergen avoidance and symptomatic relief with antihistamines and intranasal corticosteroids to escalation with inhaled corticosteroids and bronchodilators for lower airway involvement. Targeted therapies, including leukotriene receptor antagonists and monoclonal antibodies directed against IgE or interleukins, have transformed care for severe disease. A holistic approach recognising the bidirectional relationship between rhinitis, sinus inflammation and asthma is key to reducing exacerbations, improving quality of life and lowering healthcare burden worldwide.

Research from Nature Portfolio

One large-scale epidemiological analysis utilising a national health database revealed a pronounced bidirectional relationship between chronic rhinosinusitis and asthma. Individuals diagnosed with asthma faced a nearly twofold increased risk of developing sinus inflammation, while those with rhinosinusitis exhibited a similar risk elevation for subsequent asthma onset. The study highlighted that young adult men exhibited the strongest comorbidity, underscoring the need for early screening and integrated care pathways across specialties.

A histopathological investigation of nasal mucosa in patients with hypersensitivity pneumonitis provided novel insights into upper airway involvement in interstitial lung inflammation. Although focused on a distinct immunopathology, the work uncovered that chronic lymphocytic infiltration in the nasal lining correlated with cough severity and sinonasal symptom burden. These findings point to shared mucosal effector mechanisms and suggest that sampling of the upper airway may offer biomarkers for lower airway disease activity and therapeutic response.

Allergic Airway Disease Mechanisms and Management publication trend

The graph below shows the total number of articles in allergic airway disease mechanisms and management across all publications each year (not limited to Nature Index journals).

Technical terms

Airway hyperresponsiveness (AHR): Exaggerated bronchoconstrictive response to stimuli that are normally innocuous.

Eosinophil: A type of white blood cell that releases cytotoxic mediators contributing to tissue damage in allergic inflammation.

Immunoglobulin E (IgE): An antibody isotype that recognises allergens and triggers mast cell and basophil activation.

Inhaled corticosteroids (ICS): Anti-inflammatory medications delivered directly to the airway mucosa to suppress local immune responses.

T helper 2 (Th2) cell: A subset of CD4+ T lymphocytes that secrete interleukins promoting humoral immunity and allergic inflammation.

Monoclonal antibody: A biologic agent designed to target specific immune mediators such as IgE or interleukins involved in allergic pathogenesis.

References

1. Bidirectional association between asthma and chronic rhinosinusitis: Two longitudinal follow-up studies using a national sample cohort. Scientific Reports (2020).
2. Study of nasal mucosa histopathological changes in patients with hypersensitivity pneumonitis. Scientific Reports (2023).
3. The Nose and the Lung: United Airway Disease?. Frontiers in Pediatrics (2017).
4. Regulation of Interaction between the Upper and Lower Airways in United Airway Disease. Medical Sciences (2019).
5. Impact of rhinitis on asthma severity in school‐age children. Allergy (2014).